The MSSE gene predisposes to multiple invasive but selfhealing skin tumours (multiple self-healing epitheliomata). MSSE was previously mapped to chromosome 9q22-q31 and a shared haplotype in affected families suggested a founder mutation. We have refined the MSSE critical region (o1 cM, o1 Mb) between the zinc-finger gene ZNF169 and the Fanconi anaemia gene FANCC. By genetic mapping we have excluded ZNF169 and FANCC as well as PTCH (PATCHED) and TGFBR1 (transforming growth factor beta receptor type-1) genes. The CDC14B cell cycle phosphatase gene also lies in the region but screening of the complete coding region revealed no mutation in MSSE patients. Somatic cell hybrids created by haploid conversion of an MSSE patient's cells enabled screening of the MSSE chromosome 9 and showed no CDC14B deletion or mutation that abrogates CDC14B mRNA expression. Thus, CDC14B is unlikely to be the MSSE gene. We also report the first molecular analysis of MSSE tumours showing loss of heterozygosity of the MSSE region, with loss of the normal allele, providing the first evidence that MSSE is a tumour suppressor gene.
Introduction
Individuals with multiple self-healing squamous epithelioma (MSSE) develop multiple invasive skin tumours that undergo spontaneous regression leaving pitted scars, with an age of onset between 8 and 62 years. MSSE shows autosomal dominant inheritance, with most affected families originating in western Scotland. By linkage analysis, the MSSE gene was mapped to chromosome 9q and a shared haplotype was revealed, suggesting a founder mutation (Goudie et al., 1993) . Subsequently, we localized the MSSE region to 9q22.3, between D9S197 and D9S287/D9S1809 (Richards et al., 1997) . Our continued efforts to refine the MSSE critical region using new polymorphic markers have been hampered by ambiguities in the map in this region, estimated to be 2.06 cM or 2.2 Mb, 93.34-95.54 Mb from NCBI Build 35.1, http://www.ncbi.nlm.nih.gov and Rutgers combined linkage-physical map, build 35 (Kong et al., 2004) .
Chromosome 9q22.3 is relatively gene-rich and harbours several possible candidate genes, including PATCHED (PTCH), ZNF169 (encoding Kruppel-like zinc-finger protein), Fanconi Anaemia Complementation group-C (FANCC) and CDC14B. The Gorlin Syndrome gene, PTCH, is a tumour suppressor gene (TSG) that is mutated or deleted in the majority of basal cell carcinomas of the skin (Gailani et al., 1996; Holmberg et al., 1996) . The ZNF169 gene was mapped to the interval D9S196-D9S280 (Levanat et al., 1997) and was therefore considered a candidate. Previously we have shown that MSSE families share an allele at an EcoR1 RFLP in FANCC (Richards et al., 1997) thereby leaving it a possible candidate. The cell cycle regulatory phosphatase CDC14B regulates p53 (Li et al., 1997 (Li et al., , 2000 . The map position of CDC14B is ambiguous: according to radiation hybrid mapping it lies between D9S196 and D9S287 (GeneMap'99) within the MSSE critical region, but according to the genome sequence (NCBI Build 35.1) it is approximately 0.75 Mb distal to D9S287, outside the MSSE region. This discrepancy will be discussed later.
Here, we first narrowed down the MSSE interval by typing additional markers in MSSE families. Secondly, we have analysed possible candidates mapped within or close to the MSSE critical region, successfully excluding some of them. Thirdly, we have performed the first molecular analysis of MSSE tumours and have detected loss of heterozygosity (LOH), providing first evidence that MSSE is likely to be a TSG.
Results

Refining the genetic map of the MSSE interval
To reduce the MSSE interval, we performed haplotype analysis with nine new markers. However, due to gaps and ambiguities in the physical map of this region, we first had to genetically map these markers (D9S119, FBP1, AFM070xb11, AFMa086yf1, AFM203wh8, AFMa350xg1, AFM023xh8, D9S1851, TGFBR1) by typing them in 15 CEPH and three Gorlin Syndrome families with known 9q22 recombinations, along with seven previously mapped markers (ZNF169, D9S280, D9S1816, D9S196, D9S197, D9S287, D9S1809). Positional information from three Gorlin families and six CEPH recombinants (in families 1420, 1421, 13291 and 13292) allowed us to assemble an unambiguous genetic map of the region between D9S196 and D9S180 in relation to the background genetic map based on Genethon, Marshfield and deCODE genetic maps (Figure 1 ). This mapping enabled us to place TGFBR1 distal to D9S1809, outside the MSSE critical region. Similarly, a key recombinant demonstrated that AFMa086yf1 is proximal to FANCC. CDC14B was not mapped genetically because no polymorphisms were known.
Our genetic map of these markers is in agreement with the latest assembled human genome sequence (NCBI Build 35.1), with the exception of AFMa086yf1. Our recombination data clearly places AFMa086yf1 proximal to FANCC, whereas the assembled genome sequence shows AFMa086yf1 distal to FANCC. We have not been able to find any other reports of genetic mapping of AFMa086yf1.
It is important to note that D9S280 and D9S1851 were not given a physical location in the deCODE genetic map (Kong et al., 2002) because the authors were unable to resolve discrepancies between their genetic mapping and the physical draft sequence in this region. The more recent Rutgers combined linkagephysical map (Kong et al., 2004 ) also does not include D9S280, suggesting that genetic and physical maps could not be reconciled. We wonder if there is a duplication in this region that has resulted in these discrepancies. This draws support from evidence of a duplicated D9S280 locus >2 Mb distal to the first D9S280, also distal to D9S287 in the annotated genome sequence.
Genotyping of intragenic polymorphisms excludes three genes
The FANCC, ZNF169 and PTCH genes lie within the MSSE interval (D9S196-D9S287) and were thus considered as candidates. We have now typed intragenic polymorphisms in 11 MSSE families known to share a haplotype on chromosome 9q.
Affected members of LE and BL families do not share the common allele at FANCC intron 2 (CAintr2) and the LE family also does not share the common allele at FANCC intron 1 (CAintr1a) ( Table 1) . Also, affected members of families BL and LE did not share an allele with the rest of the families at a ZNF169 intronic microsatellite (Table 1) . Thus, FANCC and ZNF169 were both excluded as MSSE candidates.
Earlier we had failed to exclude PTCH (Richards et al., 1997); however, typing of an additional PTCH polymorphism (C/G at nucleotide1504-51) showed that the C allele segregates with the disease in affected LE family members, in contrast to a G allele in other families, thereby excluding PTCH as a candidate.
Haplotype analysis refines the MSSE interval
To narrow down the MSSE critical region, we analysed eight additional markers (D9S119, FBP1, AFM070xb11, AFMa086yf1, AFM203wh8, AFMa350xg1, AFM023xh8, and D9S1851) in the MSSE families (Table 1) . Affected individuals from all of the 11 families previously known to share the 9q haplotype were found to have at least one allele in common at each Figure 1 Genetic map of 9q22-q31. Marker positions determined from genetic mapping data only (not physical data). The backbone on the left shows the combined data on markers from the Genethon and Marshfield sex-averaged linkage maps and deCODE genetic map, including chromosomal orientation and the approximate genetic distance of 2 cM. To the right of the backbone is the genetic mapping data from the present study obtained from key recombinants in CEPH and Gorlin syndrome families. Vertical lines next to a marker name indicate the position of the marker (e.g. AFM070xb11 is between D9S196 and FANCC). Arrows indicate that the possible position extends beyond limits of the map shown (e.g. D9S119 is proximal to D9S197). Sloping lines indicate the position of markers with respect to each other (e.g. AFM203wh8 is distal to AFMa086yf1 and proximal to AFMa350xg1 and AFM023xh8). CDC14B is not included because it has not been mapped genetically.
The MSSE skin tumour suppressor gene S Bose et al of these marker loci, with the exception of the most distant families, BL and LE. Affected BL members did not share a common allele at D9S119 or AFM023xh8, and affected members of LE did not share the common allele at D9S1851.
Analysis of the haplotype data from the microsatellites and intragenic polymorphisms suggests several possible locations for MSSE: either in the interval ZNF169-FANCC, or distal to FANCC close to either AFM203wh8 or D9S1816 (Table 1) . However, there is a recombinant individual in family GE, who is unaffected at more than 67 years of age, shows high-risk haplotype at FANCC, PTCH, D9S287 and distal markers, but low-risk haplotype at D9S280, AFM070xb11, ZNF169 and more proximal markers (Figure 2 ). Assuming that this individual, GE6.16, is truly unaffected and is not a mutation carrier then MSSE is proximal to FANCC. Thus, the haplotype and key recombinant data suggest that the most likely position for MSSE lies within the 1 cM distance (o1 Mb), between ZNF169 and FANCC.
CDC14B is not mutated in MSSE patients
Analysis of the annotated genome sequence showed the CDC14B gene to be only 50 kb from marker AFMa086yf1. As discussed above we believe that there is a discrepancy in the genome assembly and that AFMa086yf1 may be proximal to FANCC and thus within the MSSE critical region, making CDC14B a candidate for MSSE. We screened all 15 CDC14B exons in 13 MSSE patients representing five families and eight isolated cases: no mutation was identified. We identified an intronic polymorphism, a GTG insertion in a six GTG repeat (intron 14 ntd À55) in GE4.33 (which did not segregate with MSSE in the family), one isolated MSSE case and normal individuals.
Further, to rule out large deletions that may have been missed in the heterozygous patients during mutation analysis, we created somatic cell hybrid clones, each containing a single chromosome 9 from MSSE patient LE2.7, that would allow screening of haploid DNA. All CDC14B exons were detected by PCR from these hybrid Polymorphic alleles on 9q13-9q31 segregating with the MSSE phenotype in 11 affected families. Shaded region indicates shared haplotypes. When two possible alleles are shown for an individual, it either indicates heterozygous state or that the phase could not be determined. When more than two alleles have been shown (e.g. in BL and LE), it indicates that all affected individuals within the family did not share a common allele. The relative positions of markers shown in bold have been confirmed by genetic linkage mapping.
The MSSE skin tumour suppressor gene S Bose et al clones, showing that there was no deletion in the entire coding region of CDC14B.
To rule out a promoter mutation, we detected CDC14B mRNA expression in all haploid hybrids equivalent to levels in diploid lymphoblastoid cells from a normal individual and LE2.7. Both isoforms were detected (CDC14B2 containing exons 1-14 and CDC14B1, missing exon 13), regardless of the chromosome 9 allele present. We concluded that there is no mutation, deletion, or loss of expression of CDC14B in MSSE patients.
Evidence of LOH around the MSSE interval
To investigate presence of LOH, six markers were typed in 12 tumours from five MSSE individuals: four tumours from SE3.25, three from AR2.4, one each from LE2.2 and LE2.7 and three from isolated case BH. In seven tumours no LOH was detected; however, LOH was observed in the remaining five tumours. In all cases the loss was partial, probably due to contamination with normal cells (Figure 3a) . LOH across the whole region was detected in tumour T3 from SE3.25. In three of the other tumours loss was detected at some markers but not others (Figure 3b ). There appears to be a common region of deletion distal to AFM070xb11 and D9S280 in the tumours from SE3.25. This region of LOH is within the critical region for MSSE identified from the family studies. Analysis of additional markers would be required to identify the minimal region of loss. This is hampered by a paucity of tumour material because MSSE tumours are now treated with cryotherapy rather than being surgically excised. There is a region of LOH around ZNF169 in the tumour from the sporadic MSSE patient BH but this tumour retains heterozygosity at AFM070xb11 and thus does not appear to show an overlapping region of LOH with the tumours from SE3.25. However, the markers distal to AFM070xb11 that were tested were not informative in BH so a second region of LOH in the MSSE region in this tumour cannot be ruled out.
In all informative tumours from the familial cases SE3.25 and AR2.4 the allele lost was always the normal allele rather than the allele that segregates with MSSE. Thus, it is likely that MSSE is a TSG.
Discussion
We have localized the MSSE locus to the o1 cM region between ZNF169 and FANCC based on haplotype and linkage analysis in 11 families with a common ancestor, including a key recombinant individual who is unaffected at 67 years of age. The corresponding physical distance is likely to be o800 kb, however, some discrepancies between the physical assembly of the genome and the genetic map of this region still remain. A recent assessment of the gaps in the human genome sequence showed that the region between 92 and 96 Mb on chromosome 9 (approximately D9S196-D9S180) contains duplicated sequence (Eichler et al., 2004 ), which we believe may have led to some errors in sequence assembly. The order of markers in this region confirmed by both genetic and physical maps is D9S196-ZNF169-D9S280-FANCC-D9S1816-D9S287, but there is an additional 'pseudo' D9S280 duplicated locus in the annotated genome sequence more than The MSSE skin tumour suppressor gene S Bose et al 2 Mb distal to the first and also distal to D9S287 and we wonder if this duplication may have contributed to errors in physical mapping. AFMa086yf1 is placed distal to D9S287 on the annotated genome sequence but we have shown by genetic linkage with key recombinants that AFMa086yf1 is proximal to FANCC. It is intriguing that several groups have found discrepancies in this region but we are unable to provide an explanation, apart from speculating that one possibility is a polymorphism of genome organization (such as a duplication or inversion) that differs between the DNA used for genome sequencing and that used for genetic mapping studies. There is a precedent for this: a polymorphic inversion has recently been implicated in ethnic differences in mapping of a region of chromosome 8p (Jorgenson et al., 2005) .
While we have not formally investigated whether MSSE might be caused by a duplication mutation, none of our electrophoretic gels have shown any indication of higher gene or marker dosage in affected individuals than normal individuals, and this type of mutation is unlikely for a TSG, which we believe MSSE to be.
We have excluded four plausible MSSE candidates by genetic mapping (FANCC, ZNF169, PTCH and TGFBR1). For another possible candidate, CDC14B, we found no deletions or mutations in the entire coding region, and no mutation that abrogates mRNA expression. The data that excluded deletion and loss of expression was obtained using somatic cell hybrids created from an affected individual who shares the founder genotype at the MSSE interval. This is a powerful method for excluding germline mutations that would otherwise be missed by PCR analysis of heterozygous DNA. Thus, while we have been unable to totally exclude CDC14B, it is unlikely to be the MSSE gene.
Refinement of the MSSE critical region, together with human genome sequence data has also enabled us to exclude several other possible candidate genes on 9q22-q31. Thus, the genes CORO2A (Zaphiropoulos and Toftgard, 1996) , CKS2 (Demetrick et al., 1996) , DAPK1 (Feinstein et al., 1995) , DEC1 (Nishiwaki et al., 2000) , ECM2 (Nishiu et al., 1998) , FKHL15 (Chadwick et al., 1997) , GADD45G (Suzuki et al., 1999) , GAS1 (Wicking et al., 1995) , NINJ1 (Chadwick et al., 1998) , RGS3 (Chatterjee et al., 1997) , TRK-B/NTRK2 (Slaugenhaupt et al., 1995) and GKLF implicated as TSG in colorectal cancer (Zhao et al., 2004) , all lie outside the MSSE critical region. There are at least six genes between ZNF169 and FANCC, which are positional candidates for MSSE: AL133071, FLJ14753 and AF130099 (with unknown function), FBP1, FBP 2 (fructose bisphosphatase genes) and C9orf3 (predicted to be a membrane alanine aminopeptidase). MicroRNA genes have recently been associated with cancer (Croce and Calin, 2005 ) and a cluster of three microRNA genes lies just proximal to FANCC on 9q22 (miRBase http://microrna. sanger.ac.uk, Griffiths-Jones, 2004) . These are worthy of further investigation.
Identification of LOH around the MSSE locus in tumours, with consistent loss of the normal allele, suggests that loss of function of MSSE is likely to be important for tumourigenesis. This provides the first direct evidence that MSSE fits Knudson's two-hit hypothesis and is a TSG. It is possible that this gene is also involved in the development of other tumours. Up to 65% of cutaneous squamous cell carcinoma (SCC) have LOH at a region of 9q22.3 but no mutations in PTCH or XPA were found, suggesting the existence of another TSG in this region important for sporadic SCC The MSSE skin tumour suppressor gene S Bose et al development (Ahmadian et al., 1998) . Also TSGs for other cancers are suspected to reside between 9q22-q31 (Byrom et al., 2004) . It is possible that the MSSE TSG may play a role in these other sporadic tumours.
Materials and methods
Patients and samples DNA from 161 individuals, including 49 affected and 104 unaffected or at risk members from 11 MSSE families and eight isolated MSSE cases was studied. The nomenclature used for the families is consistent with previous publications on MSSE.
We also analysed DNA from 15 CEPH families (12, 66, 104, 884, 1332, 1345, 1346, 1377 (two recombinants), 1416, 1420, 1421 (two recombinants) , 1423 (two recombinants), 13291, 13292 (two recombinants), 13293, (http://www.cephb. fr/cephdb/)) and three families with Gorlin Syndrome (Farndon et al., 1994) with known genetic recombinations in the 9q22.3 region, kindly provided by Professor Sue Povey and Professor Peter Farndon, respectively.
Analysis of 9q polymorphic markers for linkage and haplotype analysis Microsatellite markers D9S119, D9S197, D9S196, ZNF169, FBP1, D9S280, D9S1816, D9S287, AFM070xb11, AFMa086yf1, D9S1851, AFMa350xg1, D9S1809, AFM023xh8 were amplified by PCR using published primers (http:// www.gdb.org) and standard conditions. For AFM203wh8, new primer AFM203F2 (5 0 -CTG TTA CTC TGG TGA CTA CCC A-3 0 ) and published primer AFM203wh8.m were used. Two CA repeats in intron 1a and intron 2 of the FANCC were amplified (Savoia et al., 1996) . All samples were analysed by denaturing PAGE with silver staining.
Analysis of intragenic polymorphisms
A 255 bp fragment containing PTCH exon 11 and C/G polymorphism in intron 10, nt 1504-51 (Richards et al., 1997) was amplified using primers PTCF5 (5 0 -GTG TTA GGT GCT GGT GGC A-3 0 ) and PTCR5 (5 0 -CTT AGG AAC AGA GGA AGC TG-3 0 ). After NlaIII digestion the alleles were detected as C allele: 63 þ 192 bp; G allele: 18 þ 45 þ 192 bp. TGFBR1 intron 7 polymorphism (G/A at 1255 þ 24) (Gong et al., 1999) was analysed in CEPH families informative for D9S1809 by PCR-SSCP of a 248 bp fragment. Sequencing was performed to confirm results that were inconclusive.
Analysis of CDC14B PCR-SSCP with intronic primers for all 15 exons (sequences and PCR conditions available on request) was used to screen for mutations in CDC14B (Genbank Accession numbers AF023158, AF064104 and AF064105). Exons demonstrating band shifts were sequenced. All exons were screened by SSCP in patients GE4.33, SE3.25, LR4.17, JA (from BL family), MO (from LN family) and eight isolated cases. Then for final exclusion all 15 exons were directly sequenced from GE4.33 and two isolated cases.
For screening of CDC14B deletions and expression, somatic cell hybrid clones haploid for chromosome 9 were created from lymphoblastoid cells of LE2.7 and murine E2 embryonic fibroblast recipient cells using GMP Conversion Technology (GMP Genetics, Inc.). We obtained DNA from four hybrid lines each containing one of the chromosome 9 (clones 7 and 10 with one, clones 8 and 18 with the other) that is, two clones with normal chromosome 9 and two with the MSSE chromosome 9. All four clones were analysed for CDC14B deletions by PCR of each exon.
RT-PCR was performed on hybrid clones 7 and 8, lymphoblastoid cells from LE2.7 and a normal individual, mouse E2 cells. Primer sequences and PCR conditions are available on request.
LOH analysis of MSSE tumours
Normal and tumour tissue regions marked on haematoxylineosin-stained slides were dissected from sequential formalin fixed, paraffin-embedded sections. DNA obtained following proteinase K digestion (551C/overnight) was amplified and compared with DNA from peripheral blood.
Forward primers for all six markers (D9S197, ZNF169, AFM070xb11, D9S280, D9S1809, AFMa350xg1) used for LOH analysis were labelled with either HEX or 6-FAM (Invitrogen Life Technologies Ltd, UK). After 25 cycles of amplification, PCR products were analysed by 6% PAGE using an ABI377 (Applied Biosystems) with Genescan-500 TAMRA as internal size standard and Genescan software (version 2.0.2) (Applied Biosystems). LOH was scored by calculation of the ratio of the tumour DNA peaks (T1/T2) compared to that in normal DNA to give relative ratio XLOH [(T1/T2)/(N1/N2)]. XLOH ¼ 0 signifies complete allele loss, 1 signifies no LOH. We took XLOHo0.5 to represent LOH, although other groups have used values as high as o0.8 (that represents 30% LOH-containing cells contaminated with 70% normal cells) (Martignetti et al., 2000) .
